BUZZ-<a href="https://laohu8.com/S/PSNL">Personalis</a> rises as Medicare extends coverage to lung cancer test** Shares of U.S.-based cancer diagnostics firm Personalis PSNL.O rise 2.3% to $8.01 premarket
** Co says Medicare will now cover its NeXT Personal test for monitoring early-stage non-small cell lung cancer, the most common form of the disease
** Says the test tracks tiny bits of circulating tumor DNA (ctDNA) in blood that can indicate the presence of cancer; analyzes hundreds of tumor-specific mutations to guide ongoing care decisions
** Move follows Medicare approval for the same test in breast cancer patients, co says
** Medicare is the U.S. government health insurance program for people aged 65 and older
** Shares rose ~38% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments